14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ZBIO vs VRDN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Viridian Therapeutics, Inc. (VRDN) is the stronger overall head-to-head candidate over Zenas BioPharma, Inc. (ZBIO) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ZBIO carries a Unified Composite Score of 49.4/100 (HOLD) at $27.93 (N/M Forward P/E, -2747.5% operating margin), whereas VRDN carries 36.8/100 (SELL) at $29.80 (1.0x Forward P/E, -1781.4% operating margin).
Composite vs. Pillar Nuance: While ZBIO currently prints a higher short-term Unified Composite Score (49.4/100 HOLD vs. VRDN 36.8/100 SELL), VRDN captures the overall institutional head-to-head verdict (7–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-1781.4% vs. -2747.5% operating margin) and revenue trajectory (-63.5% vs. -100.0% YoY).
Technical & Structure Timing Caution: ZBIO is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.0); meanwhile VRDN trades in a Markup technical trend (SURGE options phase, RSI 72.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Biotechnology value chain with $3.5B market capitalization and -1781.4% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ZBIO vs VRDN Key Questions & Quantitative Answers
As of Nov 16, 2026, Viridian Therapeutics, Inc. (VRDN) is the stronger overall head-to-head candidate over Zenas BioPharma, Inc. (ZBIO) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ZBIO carries a Unified Composite Score of 49.4/100 (HOLD) at $27.93 (N/M Forward P/E, -2747.5% operating margin), whereas VRDN carries 36.8/100 (SELL) at $29.80 (1.0x Forward P/E, -1781.4% operating margin). Composite vs. Pillar Nuance: While ZBIO currently prints a higher short-term Unified Composite Score (49.4/100 HOLD vs. VRDN 36.8/100 SELL), VRDN captures the overall institutional head-to-head verdict (7–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-1781.4% vs. -2747.5% operating margin) and revenue trajectory (-63.5% vs. -100.0% YoY). Technical & Structure Timing Caution: ZBIO is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.0); meanwhile VRDN trades in a Markup technical trend (SURGE options phase, RSI 72.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
VRDN leads the Growth & Scale pillar: ZBIO posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -2747.5% operating margin), compared with VRDN at -63.5% YoY revenue growth and +0.0% YoY earnings growth on $26M TTM revenue (N/A gross margin, -1781.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ZBIO cumulative revenue shifted -80.0% while VRDN shifted +600.0%. In operating R&D and SG&A reinvestment, ZBIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VRDN.
VRDN screens cheaper on headline valuation multiples. ZBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas VRDN trades at 1.0x Forward P/E, 1.0x Trailing P/E, N/M PEG, and 134.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ZBIO (-265.1% ROE) versus VRDN (-83.7% ROE) capital efficiency.
In options market volatility and institutional positioning, ZBIO carries 95.3% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.16β · 59% Vol realized risk). By comparison, VRDN carries 87.7% implied volatility (20th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (1.13β · 65% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.